PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
7116.67%
Some net income increase while VET is negative at -89369.06%. John Neff would see a short-term edge over the struggling competitor.
-4.81%
Negative yoy D&A while VET is 12.77%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
404.35%
Some yoy growth while VET is negative at -1307.13%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-522.22%
Negative yoy SBC while VET is 15.70%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
293.02%
Less working capital growth vs. VET's 809.69%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
275.36%
AR growth of 275.36% while VET is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
293.02%
Lower 'other working capital' growth vs. VET's 809.69%. David Dodd would see fewer unexpected short-term demands on cash.
-292.59%
Negative yoy while VET is 4488.34%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-22.47%
Negative yoy CFO while VET is 26.25%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-37.63%
Both yoy lines negative, with VET at -227.69%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
-76.19%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
442.11%
Growth well above VET's 227.00%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
-10.83%
Both yoy lines negative, with VET at -59.81%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-428.57%
Both yoy lines negative, with VET at -23.97%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.